Introduction
Since IgA nephropathy was first reported in 1968 (1) , it has been believed that the disease has a benign prognosis and patients were followed up without treatment. However, in the middle 1980s, the prognosis of IgA nephropathy was reported to be worse than had been previously believed, and about 30 to 40% of patients developed end-stage renal disease (ESRD) (2) (3) (4) . In Japan the anti-platelet drug, dipyridamole, was often used for IgA nephropathy patients with proteinuria in the late 1980s (5) . However, its effect on renal survival has not been proved (6, 7) . Since angiotensinconverting enzyme (ACE) inhibitors have been demonstrated to be effective for proteinuria in diabetic nephropathy patients in 1986 (8) and also showed a renoprotective effect in diabetic nephropathy in 1993 (9) , ACE inhibitors have been applied for IgA nephropathy since 1994 (10) . Angiotensin receptor blockers (ARBs) were also shown to prevent renal dysfunction in diabetic nephropathy patients in 2001 (11) (12) (13) , and also began to be applied to IgA nephropathy (14, 15) . (6) . The study by Pozzi et al stimulated the trend for using steroid pulse therapy for IgA nephropathy in 1999 (16) . In Japan tonsillectomy with steroid pulse therapy is the recent trend for the therapy of IgA nephropathy (17) (18) (19) .
Immunological therapies with prednisolone and immunosuppressive drugs including cyclophosphamide and azathioprine have been tried in severe proteinuric cases or progressive cases of IgA nephropathy
Clinicians are naturally influenced by the trends in treatment of IgA nephropathy. Especially when double-blind randomized controlled studies demonstrated a significant effect of steroid pulse therapy in IgA nephropathy (20) 
Statistical analysis
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Results
Baseline data at renal biopsy and pathological evaluation
At the renal biopsy there was no significant difference in the baseline data including age, blood pressure, and serum creatinine among the 4 groups. However, proteinuria at the time of renal biopsy was significantly higher in the PSL group than in the other 3 groups (Table 1) . Renal morphological data was not different among the 4 groups ( Table 1) . (Fig. 1) .
T a b l e 1 . Cl i n i c a l a n d P a t h o l o g i c a l Da t a a t Re n a l B i o p s y
As for remission, 20% of patients treated with ACEI or ARB showed complete remission (CR) (Fig. 2) (Fig. 3) .
In the PSL group, proteinuria was reduced to less than 1 g/day in most cases, and 16 cases (43%) achieved complete remission with less than 0.2 g/gCr (Fig. 2) , and 3 patients (8%) reached ESRD (Fig. 1) . Kaplan-Meyer renal survival was better in the PSL group than in the no treatment group or anti-platelet group, but the difference was not significant (Fig. 3) .
Clinical features of patients who reached complete remission with steroid therapy
The (23) . In the present study, 25% of patients without treatment spontaneously went into 
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Effectiveness of RAS blockade on renal prognosis
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